Experimental clot inhibitors match conventional drugs | Science News



Science News is a nonprofit.

Help us keep you informed.


Experimental clot inhibitors match conventional drugs

10:54am, December 19, 2006

From Orlando, Fla., at a meeting of the American Society of Hematology

Two new drugs—one in pill form and another requiring only a single weekly injection—prevent dangerous blood clots in leg veins just as well as do standard treatments that require daily shots, two European research teams report.

In one study, scientists in Sweden focused on people who were undergoing knee-replacement surgery, a group at high risk of developing clots. The researchers gave 1,029 of the patients an experimental oral drug called dabigatran etexilate a few hours after surgery and then daily for at least a week. Another group of 512 patients received a standard treatment, enoxaparin (Lovenox)—a derivative of the blood thinner heparin—by daily injection for a week, starting 12 hours before surgery.

Slightly more than one-third of the patients in each group developed a severe leg clot called deep-vein thrombosis during the 8 days after surgery, reports p

This article is only available to Science News subscribers. Already a subscriber? Log in now. Or subscribe today for full access.

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content